On November 13, the first session will take place within the IV Progress Reports Valdecilla Program, which will feature presentations by Julia Garcia Reyero and Miriam Sánchez Escamilla.
TItle: “MUTATIONAL PROFILE OF LYMPHOMAS B WITH PLASMOCELLULAR DIFFERENTIATION“
Speaker: Julia Garcia Reyero
Julia Garcia Reyero has a degree in Medicine, from the Universidad San Pablo CEU (Madrid), in 2015. Currently, she is a fourth year resident of the specialty of Pathology, (MIR), at the Marqués de Valdecilla University Hospital.
In addition, he is a member of the research group: IDIVAL Translational Hematopathology.
PhD student from the University of Cantabria, focusing his future doctoral thesis on the molecular pathogenesis of B lymphoma with plasma cell differentiation under the direction of Dr. Montes-Moreno.
To date, he has published an original article in journals integrated in Pubmed (Urquieta Lam et al MYD88L265P mutated IgA lymphoplasmacytic lymphoma, Histopathology. 2019 Oct; 75 (4): 608-612. Doi: 10.1111 / his.13921) and presented several communications in national and international conferences related to his doctoral thesis.
Title “My experience as MSK visiting-investigator”
Speaker: Miriam Sánchez Escamilla
Miriam Sánchez Escamilla has a degree in Medicine from the University of Murcia in 2012. Later she completed her residency in Hematology and Hemotherapy in Santander, from 2013 to 2017 and during it she was able to enjoy a 2-month external rotation at the Memorial Sloan Kettering in Nueva York in the hematopoietic transplant team.
After finishing his residency, he managed to be a recipient of the Lopez-Albo-Wenceslao Scholarship in order to continue his training in cell therapy. This scholarship has allowed him to make a 13-month stay at the MSKCC, in New York by Dr. Miguel Angel Perales, learning about new lines of cell therapy, mainly CAR-T cells and also, continuing his training in hematopoietic transplantation and its complications.
After his return, he has dedicated himself to preparing the Hospital, together with his service, to cope with the arrival of CAR-T cells and, in addition, they have recently presented to the ISCIII an independent clinical research project, based on the prophylactic use of anti-CMV lymphocytes.
All sessions will take place at 2:00 pm in Hall 16 of the Marqués de Valdecilla University Hospital (maximum capacity of 30 people). The talk of each speaker will be about 20 minutes followed by a small debate. In addition, at the end a small agape will be served to continue the conversation and encourage interaction between participants and attendees.
Attendance certificates will be issued if 80% of the sessions are attended throughout the academic period.
Any questions or clarifications can be contacted at proyectos1@idival.org
